Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

CMO Industry Thins Out

Oct 2, 2014

The trend of exits from the CMO industry looks to be gaining momentum.

Contract Services Ride High As Funding Floods Biopharma

Sep 1, 2014

The contract services industry?s success is largely a result of the improved financial environment, rather than an increased acceptance of outsourcing.

When Payers Refuse to Cover New Drugs, CMOs Take a Hit

More health systems are saying no to reimbursements for new drugs; CMOs must adjust strategies.
Aug 4, 2014

More health systems are saying ?no? to reimbursements for new drugs; CMOs must adjust strategies.

Positive Outlook for Outsourcing

Contract services ride high as funding floods bio/pharma.
Aug 1, 2014

Contract services ride high as funding floods bio/pharma.

Health Systems Raise the Bar on Reimbursing New Drugs

As payers refuse to cover new drugs, CMOs take a hit.
Jul 2, 2014

As payers refuse to cover new drugs, CMOs take a hit.

Are CMOs Out of Synch With Market Realities?

Why can't the CMO industry break through to manufacture a greater share of drugs?
May 30, 2014

Why can't the CMO industry break through to manufacture a greater share of drugs?

Stuck in Neutral

The CMO industry's value proposition is limiting its market penetration.
May 2, 2014

The CMO industry's value proposition is limiting its market penetration.

How Will CMO Ownership Changes Impact Market?

Changes in company ownership shake up the CMO industry.
Apr 1, 2014

Changes in company ownership shake up the CMO industry.

Under New Ownership

Changes in company ownership shake up the CMO industry.
Mar 2, 2014

Changes in company ownership shake up the CMO industry.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here